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Background: Platinum-based therapy is an effective treatment for a subset of triple-negative breast cancer and ovarian cancer
patients. In order to increase response rate and decrease unnecessary use, robust biomarkers that predict response to therapy
are needed.
Patients and methods: We performed an integrated genomic approach combining differential analysis of gene expression
and DNA copy number in sensitive compared with resistant triple-negative breast cancers in two independent neoadjuvant
cisplatin-treated cohorts. Functional relevance of significant hits was investigated in vitro by overexpression, knockdown and
targeted inhibitor treatment.
Results: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have
both increased DNA copy number and gene expression in the platinum-sensitive cases. Increased level of expression of these
two genes was also associated with platinum but not with taxane response in ovarian cancer. As a functional validation, we
found that overexpression of BLM promotes DNA damage and induces sensitivity to cisplatin but has no effect on paclitaxel
sensitivity.
Conclusions: A biomarker based on the expression levels of the BLM and FANCI genes is a potential predictor of platinum
sensitivity in triple-negative breast cancer and ovarian cancer.
Key words: platinum-based chemotherapy, gene expression-based predictor of treatment sensitivity, triple-negative breast
cancer, ovarian cancer
Introduction
BRCA1 plays an important role in response to replication stress
and repair of stalled or collapsed replication forks, and complete
absence of functional BRCA1 leads to defective error-free
homologous recombination-type double strand break repair.
BRCA1/ tumors are particularly sensitive to platinum-
containing chemotherapy and inhibitors of Poly [ADP-ribose]
polymerase 1 (PARP1), whereas BRCA wild-type cancers showed
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a more limited response to these agents [1]. Platinum salts gener-
ate both interstrand and intrastrand cross-links that slow or stall
replication forks [2]. Stalled replication forks may collapse into
double-strand breaks (DSBs) and/or become sites for transle-
sional synthesis-induced mutagenesis, potentially causing gen-
ome instability.
Platinum-sensitive triple-negative breast cancers (TNBC) and
serous ovarian cancers carry extensive genomic rearrangements
and allelic imbalance suggesting these cancers may share similar
defects in DNA repair acquired through alternative mechanisms
than through BRCA1 loss [3]. The overall level of such genomic
aberrations can be characterized and quantified by a recently de-
veloped clinical measure, the ‘HRD score’ [3–5]. These results
suggest that platinum sensitivity may be related to a functional
defect that occurs when BRCA1 levels are insufficient and a bio-
marker indicative of such defects may be predictive of sensitivity
to DNA cross-linkers such as platinum agents.
To explore and define specific molecular alterations that might
be associated with cisplatin sensitivity, we combined differential
analysis of gene expression and DNA copy number in cisplatin
sensitive compared with cisplatin-resistant TNBC.
Materials and methods
Breast cancer cohorts
This study is based on previously published clinical and molecular data
from two cisplatin-treated triple-negative breast cancer trials, cisplatin 1 and
cisplatin 2 [3, 6]. SNP data are available from the National Center for
Biotechnology Information Gene ExpressionOmnibus (GEO) at GSE28330,
and RNA expression data for cisplatin 1 are available GEO atGSE18864.
Data acquisition and data generation
Gene expression data based on the Affymetrix HGU133plus2 platform
were generated from a subset of the cisplatin 2 cohort from which suffi-
cient material was available as described previously [6] with the exception
that the samples were not subjected to double amplification. Data avail-
able from GEO at GSE103668. Gene expression data from the ovarian
cancer trial OV-01 [7] based on the Affymetrix HGU133A platform were
acquired fromGEO at GSE15622.
Cell lines
Breast cancer cell lines MDA-MB-231, MDA-MB-436, MDA-MB-453,
HCC38, HCC1143, HCC1937 and BT549 were cultured in vitro and sub-
jected to DNA damage. Transfections of siRNA and plasmid DNA were
performed using Lipofectamine RNAiMAX or Lipofectamine 2000 (Life
Technologies), respectively.
For full experimental details, see supplementary Methods, available at
Annals of Oncology online.
Results
Identification of genes associated with cisplatin
response
We performed a leave-one-out (LOO) differential gene expres-
sion analysis in two independent cisplatin-treated TNBC cohorts
separately to identify genes significantly associated with response.
Permutation testing identified 12 genes where expression was sig-
nificantly associated with platinum response in both cisplatin
TNBC cohorts (supplementary Table S1 and Figure S1, available
at Annals of Oncology online, Figure 1A). A similar LOO analysis
of the DNA copy numbers were performed. This identified 234
genes associated with cisplatin response in both cisplatin TNBC
cohorts (supplementary Table S2 and Figure S1B, available at
Annals of Oncology online, Figure 1B). Only two genes were iden-
tified in both analyses for association with platinum sensitivity,
the Bloom helicase (BLM) and the Fanconi anemia complemen-
tation group I (FANCI) genes, both located at chromosome
15q26. The copy number of both genes was significantly higher in
the cisplatin-sensitive tumors in both TNBC cohorts (BLM:
cisplatin-1, P¼ 0.003, cisplatin-2, P¼ 0.008, FANCI: cisplatin-1,
P¼ 0.003, cisplatin-2, P¼ 0.003, supplementary Figure S1C,
available at Annals of Oncology online). Both BLM and FANCI
showed DNA copy number gain in 33% of sensitive versus 0% of
resistant tumors in cisplatin-1, and gain in 44% of sensitive ver-
sus 12% of resistant tumors in cisplatin-2. Similarly, in both co-
horts cisplatin-sensitive tumors had significantly higher BLM and
FANCI mRNA expression (BLM: cisplatin-1, P¼ 0.0028;
cisplatin-2, P¼ 0. 0075; Figure 1C and D, FANCI: cisplatin-1,
P¼ 0.0036; cisplatin-2, P¼ 0.0125; Figure 1E and F).
As validation, gene expression levels of BLM and FANCI as
measured by Affymetrix U133 microarray were significantly cor-
related with results obtained by qRT-PCR for the same samples
(BLM, r¼ 0.87; FANCI, r¼ 0.76; supplementary Figure S1D and
E, available at Annals of Oncology online). Western blot analysis
in protein extracts from a series of tumor samples (supplemen-
tary Figure S1H, available at Annals of Oncology online) with
matched array-based mRNA measurements showed good correl-
ation between mRNA and protein levels for BLM (Spearman
r¼ 0.68, P¼ 0.0023; supplementary Figure S1F, available at
Annals of Oncology online), but not for FANCI (Spearman
r¼0.01, P¼ 0.97, supplementary Figure S1G, available at
Annals of Oncology online).
We found the expression level of BRCA1 transcript as meas-
ured by qRT-PCR significantly associated with cisplatin resist-
ance [3, 6]. When we tested association of the ratio of average of
BLM and FANCI levels divided by BRCA1 levels frommicroarray
expression versus cisplatin response, the ratio was significantly
higher in the cisplatin-sensitive tumors in both cohorts (cis-
platin-1, P¼ 0.0230; cisplatin-2, P¼ 0.0023; Figure 1G and H).
To further validate these findings, we acquired a publicly avail-
able gene expression data set from a serous ovarian cancer trial of
either carboplatin monotherapy or paclitaxel monotherapy [7].
The average expression levels of BLM and FANCI were signifi-
cantly higher in the carboplatin-sensitive ovarian cancers
(P¼ 0.026 and P¼ 0.036, respectively, Figure 1I and J). The ratio
of BLMþ FANCI/BRCA1 was also significantly higher in carbo-
platin-sensitive ovarian cancers (P¼ 0.026, Figure 1K).
Altogether, these data indicate that the expression levels of
BRCA1 are inversely correlated with those of BLM and FANCI.
Moreover, the association of BLM and FANCI with paclitaxel re-
sponse was not significant and the trend was in the opposite dir-
ection (Figure 1L and N), suggesting that the correlations might
be cisplatin or drug class specific.
The performance of the ratio of BLMþ FANCI/BRCA1 to pre-
dict platinum response was also compared with previously
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published genomic scar or gene expression-based signatures in the
cisplatin-1 and cisplatin-2 cohorts. This gene expression ratio per-
formed better than the previously published predictors (supple-
mentary Figures S2–S4, available at Annals of Oncology online). The
BLMþ FANCI/BRCA1 expression ratio also performed better in
the platinum monotherapy-treated serous ovarian cancer cohort
[7] and a platinum-treated gastric cancer cohort (supplementary
Figures S5 and S7, available at Annals of Oncology online), but had
no predictive power in non-platinum-treated ovarian cancer sam-
ples (supplementary Figure S6, available at Annals of Oncology
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Figure 1. BLM and FANCI are signiﬁcantly associated with response to cisplatin chemotherapy. Scatter-plots of LOO analysis in cisplatin-1
and cisplatin-2 cohorts identiﬁes BLM and FANCI as the only two genes that show signiﬁcant association with response in both clinical trials,
based on both gene expression data (A) and copy number aberration data (B). Red dashed lines indicate signiﬁcance thresholds based on
permutation testing. Color intensity indicates overlapping genes. Association between array expression of BLM, FANCI, and the ratio of
BLMþFANCI expression to BRCA1, and response to cisplatin chemotherapy in cisplatin-1 (C, E, G), cisplatin-2 (D, F, H) and OV01 carboplatin-
treated (I, J, K) and OV01 paclitaxel-treated (L, M, N) cohorts. Red dots indicate the BRCA1 mutant cases.
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online). It did not predict response to therapy in non-platinum-
treated neoadjuvant triple-negative breast cancer cohorts and it did
not have prognostic power in non-platinum-treated breast cancer
cohorts (see supplementary Figures S8–S14, available at Annals of
Oncology online).
Relationship of BLM and BRCA1 expression and
sensitivity to DNA damaging agents in cell lines
BLM and BRCA1 protein levels were measured in a panel of
breast cancer cell lines by Western blot analysis (Figure 2A) and
densitometry quantitation of expression ratios are displayed in
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Figure 2. Relationships of BLM, FANCI, and BRCA1 expression levels in breast cancer cell lines and association with therapy sensitivities. (A)
Western blot analysis of BLM, BRCA1, and Actin protein abundance in a panel of breast cancer cell lines. BT549, HCC1143, HCC38, MDA231,
and MDA453 are BRCA1 wild-type genotype. HCC1937 and MDA436 are BRCA1 mutated (B) Densitometry of Western blot in A for quantiﬁca-
tion of BLM/Actin and (C) BRCA1/BLM ratio. (D–G) Bar plots of IC50 to treatments in panel of cell lines. Breast cancer cells lines were irradiated
with increasing doses of UV-C or subjected to cisplatin, olaparib or paclitaxel treatment, and 4 weeks later assayed for colony formation. Error
bars represent the standard deviation between three independent experiments. (D) IC50 to cisplatin (E) IC50 to UV-C (F) IC50 to PARP-inhibi-
tory olaparib (G) IC50 to paclitaxel. (H) Western blot showing the effect of shRNA BRCA1 or shLuciferase control (shLuc) on expression of BLM
(left side) and FANCI (right side) in U2OS cells. GAPDH is shown as a loading control. (I) Western blot demonstrating gene-speciﬁc siRNA
knockdown of BLM or FANCI expression in BT549 breast tumor cells. (J) Bar plots indicate the ratio of IC50 for the cisplatin (black bars) and
paclitaxel (gray bars) in gene-speciﬁc siRNA-treated cells, relative to scramble control siRNA-treated cells. (K) Western blot for endogenous
BLM and HA-tag in MDA231 cells transfected with control vector (lane 1), HA-tag BLM cDNA (BLM, lane2), HA-tag BLM co-treated with BLM
helicase small molecule inhibitory (BLMþ BLMi, lane 3), and HA-tag BLM co-treated with 50 nM siRNA BLM (BLMþ siBLM, lane 4). (L) Bar plots
indicate the ratio of IC50 for the cisplatin in MDA231 cells treated with control vector (black bar), HA-tag BLM cDNA (BLM, medium gray bar),
HA-tag BLM co-treated with BLM helicase small molecule inhibitory (BLMþ BLMi, dark gray bar), and HA-tag BLM co-treated with 50 nM
siRNA BLM (BLMþ siBLM, light gray bar).
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bar plots (Figure 2B and C). Two cell lines without BRCA1 se-
quence mutations (BT549, HCC1143) and the HCC38 cell line in
which BRCA1 expression is suppressed by methylation displayed
high BLM/actin and low BRCA1/BLM expression ratios. Two
other BRCA1wt cell lines (MDA231 and MDA453) displayed
relatively lower BLM/actin and higher BRCA1/BLM expression
ratios. On the other hand, HCC1937 and MDA436, which are
known to be BRCA1-null, displayed high levels of BLM expres-
sion normalized to actin along with very low BRCA1/BLM ex-
pression ratios. This cell line panel was evaluated for sensitivity to
various treatments by colony formation assay. The three panels
of Figure 2D–F show that the pattern of sensitivity to cisplatin,
UV radiation treatment, and PARP inhibitor olaparib across the
panel of cell lines is associated with the pattern of relative expres-
sion of BRCA1/BLM and BLM/actin. The two sequence-mutated
BRCA1 cell lines and the three cell lines with low BRCA1/BLM
and high BLM/actin have greater sensitivity to all three treat-
ments. The two cell lines with low BLM and high BRCA1/BLM
(MDA231, MDA453) are relatively resistant to the same treat-
ments. In contrast, there is no apparent relationship between
BLM and BRCA1 expression with the pattern of sensitivity to the
microtubule stabilizer paclitaxel (Figure 2G). These data suggest
that BRCA1/BLM protein ratio may be predictive of the sensitiv-
ity to canonical DNA damaging agents (e.g. cisplatin, UV, and
olaparib) but not necessarily to agents like paclitaxel that work
through distinct mechanisms.
Effect of modulating BRCA1 expression on BLM
and FANCI expression
In order to elucidate the correlation between BRCA1, BLM and
FANCI expression levels, we knocked down endogenous BRCA1
in U2OS cells in which the role of BRCA1 in the double-strand
break repair (DSBR) response has been well studied. After 1 week
of treatment following transfection of BRCA1-specific shRNA,
the expression of BRCA1, BLM, and FANCI were measured by
Western blot analysis (Figure 2H). Cells in which BRCA1 was
knocked-down showed increased expression of BLM protein
compared with control cells treated with shRNA specific to luci-
ferase (Figure 2H, left panel). Given that BRCA1 is a known nega-
tive transcriptional regulator of BLM [8], it is possible that the
increase in BLM protein levels in BRCA1 depleted cells is a direct
consequence of this negative regulation. On the other hand, the
expression levels of FANCI did not change upon knockdown of
BRCA1 by shRNA (Figure 2H, right panel).
Effect of modulating BLM and FANCI expression on
sensitivity to cisplatin and taxanes
Since BLM showed a good correlation between mRNA and pro-
tein expression levels and was up-regulated by down-regulation
of BRCA1, further functional validation was carried out. We car-
ried out knockdown experiments in BT549 breast cancer cells,
which inherently express high levels of BLM. Gene-specific
siRNA treatment resulted in reduced protein expression of BLM
as determined by Western blot (Figure 2I). In these cells, the
IC50s for cisplatin and paclitaxel were determined by colony for-
mation assay. The knockdown of either BLM or FANCI by siRNA
resulted in greater resistance to cisplatin but no significant effect
on sensitivity to paclitaxel (Figure 2J). Given that cell cycle state
can influence chemosensitivity, we examined whether a change in
cell cycle upon BLM and/or FANCI depletion could explain the
decreased chemosensitivity to cisplatin. Loss of neither BLM
(siBLM) nor FANCI (siFANCI) had a significant effect on the cell
cycle state (supplementary Figure S15A and B, available at Annals
of Oncology online). This further suggests a direct link between
BLM and/or FANCI levels and sensitivity to DNA damaging
agents.
We tested the reverse hypothesis by overexpressing BLM using
anHA-tagged lentivirus expression vector inMDA231 cells, which
display low levels of BLM and relative resistance to cisplatin.
Overexpression was assessed byWestern blot analysis for endogen-
ous BLM or for the HA-tag (Figure 2K). In order to address the
specificity of this effect, we used siRNA-mediated knockdown of
BLM, which reduced the expression levels of both endogenous and
HA-tagged BLMprotein.We also tested the effect of adding a small
molecule inhibitor of BLM (BLMi), which can suppress BLM ac-
tivity without affecting BLM protein levels (Figure 2K, lanes 3 and
4; supplementary Figure S16, available at Annals of Oncology on-
line). As shown in Figure 2L, overexpression of BLM resulted in
decrease in the IC50 (greater sensitivity) to cisplatin. This effect
was reversed by treatment with the BLM helicase inhibitor (BLMi)
and by siRNA knockdown of BLM. These results suggest that
increased BLM expression levels and specifically BLM helicase ac-
tivity promotes increased sensitivity to cisplatin.
BLM overexpression increases spontaneous and
cisplatin-induced DNA damage
To determine whether BLM expression levels affect the accumula-
tion of DNA damage in breast cancer cells, we carried out im-
munofluorescence for markers of DNA damage in MDA231 cells
in which BLM expression levels or activity was modulated.
Overexpression of BLM resulted in no detectable difference in
spontaneous or cisplatin-induced BRCA1 foci but did suppress
RAD51 focus formation (supplementary Figure S17, available at
Annals of Oncology online). This is consistent with reports that
BLM can displace RAD51 localization at damaged replication forks
[9]. Since RAD51 is required for homologous recombination-
dependent and recombination-independent DSBR mechanisms at
stalled replication forks [10], such loss of RAD51 recruitment to
sites of DNA damage in BLMoverexpressing cells could further ex-
plain the increased sensitivity of BLM overexpressing cells to
stalled fork-inducing agents like cisplatin (Figure 2L).
Overexpression of BLM also resulted in increased spontaneous
DNA damage as evidenced by increased c-H2AX and phospho-
53BP1 (53BP1-p) foci in the absence of any drug treatment (sup-
plementary Figure S18, available at Annals of Oncology online;
Figure 3a, black bars in Figure 3C and D). This increase in DNA
damage is greater in cells after 4-h treatment with cisplatin
(Figure 3B, gray bars in Figure 3C and D). The addition of a small
molecule BLM helicase inhibitor (BLMi) or siRNA to BLM
(siBLM) blocks the effect of BLM overexpression on DNA dam-
age foci. The accumulation of endogenous DNA damage (as seen
by c-H2AX and 53BP1-p foci in untreated cells) as well as
cisplatin-induced DNA damage in BLM overexpressing cells, fur-
ther explains the increased sensitivity of BLM overexpressing cells
to cisplatin (Figure 2L).
Annals of Oncology Original article
Volume 29 | Issue 4 | 2018 doi:10.1093/annonc/mdy049 | 907
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/4/903/4857262 by H
ungary EISZ C
onsortium
 user on 05 M
arch 2019
Discussion
In this study, we identified two neighboring genes, BLM and
FANCI, with consistent copy gain and overexpression in cisplatin
sensitive primary breast tumors. The association between this
three-gene signature of high BLMþ FANCI/BRCA1 and plat-
inum sensitivity was confirmed in an independent cohort of ser-
ous ovarian cancer treated with single agent carboplatin.
Through in vitro studies, we found that chronic repression of
BRCA1 expression in cell lines led to an increase in BLM expres-
sion and no change in FANCI expression suggesting a possible
compensatory or direct transcriptional effect on BLM in the set-
ting of low or insufficient BRCA1. Our findings are consistent
with previous reports that BRCA1 regulates transcription of BLM
in prostate cancer cell lines with overexpression of BRCA1 result-
ing in down regulation of BLM [8].
BLM has recently been shown to play an important role at
stalled replication forks [11, 12]. Unlike BRCA1, which is
required for the stability of stalled replication forks, loss of BLM
does not result in its degradation. Instead, BLM has been shown
to help restart the stalled forks while suppressing firing of new
origins in response to replication stress. An increase in spontan-
eous DNA damage, especially accumulation of 53BP1-p foci in
BLM overexpressing cells (Figure 3), is suggestive of degrad-
ation and/or collapse of spontaneously arising stalled replica-
tion forks.
Homologous recombination (HR) is required for repair of
cisplatin-induced damage, as the loss of HR factors such as
BRCA1 and BRCA2 increases cisplatin sensitivity [13, 14]. Both
pro- and anti-HR roles have been described for BLM. Its function
in DNA end resection and the ability to promote DNA repair syn-
thesis in D-loops supports HR, while the disruption of RAD51
filament formation, the disruption of D-loops and the dissol-
ution of double Holliday junctions opposes HR [15–18]. One hy-
pothesis to explain these results is that at increased BLM levels
the anti-HR functions of the protein dominate, leading to
increased cisplatin sensitivity.
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Figure 3. Increased DNA damage upon BLM overexpression in MDA231 cells. MDA231 cells were infected with control vector or HA-tag BLM
cDNA (BLM) and co-treated with 20mM BLM small molecule inhibitory (Bi) or 100 nM siBLM (si). Cells were mock treated (cisplatin: 0 h, A) or
treated with 10 mM cisplatin for 4-h (cisplatin: 4 h, panel B) and released for 24 h. Immunoﬂuorescence for phospho-H2Ax and phospho-
53BP1 was carried out and nuclei counterstained with DAPI. (A) Representative immunoﬂuorescent images for indicated markers in mock
treated cells (cisplatin: 0 h) indicating spontaneous DNA damage foci. (B) Representative immunoﬂuorescent image in cells treated with
10mM cisplatin for 4 h (cisplatin: 4 h) indicating drug induced damage foci. All images were obtained at the same magniﬁcation and exposure
time. All images were analyzed in parallel for each experiment. (C and D) Cells containing foci recognized by relevant antibodies in immuno-
ﬂuorescence assays, were identiﬁed and counted. At least 100 cells were counted for each category of foci at each time point. Bar plots indi-
cate percentages of cells, noted above, that contain cH2AX-p foci (C) and PB53-p foci (D) in mock treated cells (cisplatin: 0 h, black bars) and
10mM cisplatin treated cells (cisplatin: 4 h, gray bars).
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Reduced HR in BLM overexpressing cells should cause im-
paired repair of DSBs generated at cisplatin interstrand cross-
links. However, cisplatin-induced single-strand lesions are much
more common [19]; therefore, the observed damage foci may
mostly arise at replication forks that encounter single-strand le-
sions. It has been shown previously that RAD51 is required for ef-
ficient repair and restart of stalled replication forks in an HR-
dependent and HR-independent manner [10]. Disruption of
RAD51 filament formation by BLM could antagonize post-
replication repair promoted by BRCA1, consistent with a BLM
function that requires helicase activity, and explaining the simi-
larity of the consequences of low BRCA1 or high BLM. Given that
we do not see a disruption of BRCA1 foci in BLM-overexpressing
cells despite an apparent reduction in Rad51 foci formation, we
cannot rule out that cisplatin sensitivity observed in BLM-
overexpressing cells is at least in part related to a BRCA1-
independent pathway wherein loss of RAD51 at the sites of DNA
damage sensitizes the BLM overexpressing cells to cisplatin.
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